Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis

NCT02933502 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries, Inc. as lead sponsor.

NCT NCT02933502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02933502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2016
Completion date
January 2, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

scalp psoriasis